BG
ABBV icon

Bellevue Group’s AbbVie ABBV Stock Holding History

Bellevue Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-200
Closed -$9K – 202
2019
Q1 		$9K Buy
+200
New +$16.4K ﹤0.01% 137

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bellevue Group's ABBV Position: Q1 2026 in Review

Bellevue Group reduced its AbbVie (ABBV) stake by 31% in Q1 2026, selling an estimated $9.16M and leaving 93,567 shares worth $20.3M. The position accounts for 0.48% of the portfolio, ranked #50.

Bellevue Group first reported a position in ABBV in Q1 2016 and has held it in 34 quarters since. The position peaked at $50.5M in Q1 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Bellevue Group held 93,567 shares of AbbVie worth $20.3M as of Q1 2026.
  • Bellevue Group sold 41,292 AbbVie shares in Q1 2026, an estimated $9.16M.
  • AbbVie made up 0.48% of Bellevue Group's portfolio in Q1 2026, its #50 holding.
  • Bellevue Group first reported a position in AbbVie in Q1 2016 and has held it in 34 quarters since.
  • Bellevue Group's AbbVie position peaked at $50.5M in Q1 2022.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.